Literature DB >> 2631477

[Pharmacokinetics and metabolism of gallopamil].

M Eichelbaum1.   

Abstract

Despite its almost complete absorption following oral administration, gallopamil has an absolute bioavailability of only 15% due to an extensive hepatic first-pass metabolism. During multiple oral dosing bioavailability increases to approximately 25% indicating a partial saturation of first-pass metabolism. Since the half-life time of gallopamil is on average 3-6 h a minimum of three times daily dosing of the instant-release 50 mg tablet is required in order to maintain therapeutic plasma concentrations. The sustained-release 100 mg tablet which recently became available has a relative bioavailability comparable to the instant release preparation. Due to the delayed drug liberation therapeutic plasma concentrations are maintained for 24 h following once or twice daily administration of this drug preparation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2631477

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  5 in total

1.  Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing.

Authors:  A S Gross; M Eichelbaum; K Mörike; G Mikus
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 2.  Calcium antagonists and silent myocardial ischaemia.

Authors:  G Steinbeck
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 4.  Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

5.  Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease.

Authors:  M Siepmann; B R Rao; W Kirch
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.